The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Phase I/II TG01 study exploring the use of vaccination in RAS-mutated myeloma
Fredrik Schjesvold, MD, PhD, Oslo Myeloma Center, Oslo, Norway, discusses the Phase I/II TG01 study (NCT05841550) exploring the use of vaccination in RAS-mutated multiple myeloma (MM). Dr Schjesovold outlines the main aims of the study, the possible difficulty in obtaining high response rates, and the potential of vaccines in combination with other therapies. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
